Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription 22.02.2021 1 Am J Clin Pathol 1 Ann Surg 6 Ann Thorac Surg 2 BMC Cancer 4 Br J Cancer 4 Cancer Chemother Pharmacol 1 Cancer Lett 2 Clin Cancer Res 3 Clin Lung Cancer 2 Eur J Cancer 2 Hum Pathol 2 Int J Radiat Oncol Biol Phys 1 J Clin Invest 1 J Clin Oncol 1 J Surg Oncol 2 J Thorac Cardiovasc Surg 10 J Thorac Oncol 2 Lancet 1 Lancet Oncol 1 Lung Cancer 4 N Engl J Med 1 Nat Med 1 PLoS Comput Biol 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. DE MICHELE S, Remotti HE, Del Portillo A, Lagana SM, et al
   SATB2 in Neoplasms of Lung, Pancreatobiliary, and Gastrointestinal Origins.
   Am J Clin Pathol. 2021;155:124-132.
   PubMed         Abstract available
   
   

   
   Ann Surg

2. HIRPARA DH, Coburn N, Darling G, Kidane B, et al
   Symptom Assessment Following Surgery for Lung Cancer: A Canadian Population-Based Retrospective Cohort Study.
   Ann Surg. 2021 Feb 10. pii: 00000658-900000000-93697.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

3. HELUAIN V, Hermant C, Borel C, Meilleroux J, et al
   Bronchoscopic Treatment of Endobronchial Inflammatory Myofibroblastic Tumors.
   Ann Thorac Surg. 2021;111:e109-e111.
   PubMed         Abstract available
   
   
4. BHAGAT R, Swanson SJ, Hammer MM, Mallidi HR, et al
   Multimodality Curative Treatment of IIIA/T4 Lung Adenocarcinoma.
   Ann Thorac Surg. 2021;111:e73-e75.
   PubMed         Abstract available
   
   
5. DUTTA S, Vo T, Lo WC, Iyer A, et al
   Large Isolated Benign Metastasizing Leiomyoma of the Lung.
   Ann Thorac Surg. 2021;111:e147.
   PubMed        
   
   
6. DALMIA S, Boele F, Absolom K, Brunelli A, et al
   Shared decision-making in early stage non-small cell lung cancer: A systematic review.
   Ann Thorac Surg. 2021 Feb 10. pii: S0003-4975(21)00237.
   PubMed         Abstract available
   
   
7. LAMPRIDIS S
   Salvage Surgery Following Definitive Chemoradiotherapy for Non-Small-Cell Lung Cancer.
   Ann Thorac Surg. 2021 Feb 10. pii: S0003-4975(21)00262.
   PubMed        
   
   
8. TANAKA Y, Yamamoto H, Sato M, Toyooka S, et al
   Preoperative cumulative smoking dose on lung cancer surgery in a Japanese nationwide database.
   Ann Thorac Surg. 2021 Feb 15. pii: S0003-4975(21)00281.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. ESTER M, Culos-Reed SN, Abdul-Razzak A, Daun JT, et al
   Feasibility of a multimodal exercise, nutrition, and palliative care intervention in advanced lung cancer.
   BMC Cancer. 2021;21:159.
   PubMed         Abstract available
   
   
10. CHEN J, Sun M, Zhou M, Lu R, et al
    Associations between I/D polymorphism in the ACE gene and lung cancer: an updated systematic review and a meta-analysis.
    BMC Cancer. 2021;21:158.
    PubMed         Abstract available
    
    

    
    Br J Cancer

11. CHEUNG VTF, Gupta T, Olsson-Brown A, Subramanian S, et al
    Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Br J Cancer. 2020;123:207-215.
    PubMed         Abstract available
    
    
12. PAZ-ARES L
    Foreword to 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.
    Br J Cancer. 2020;123.
    PubMed        
    
    
13. EVISON M
    The current treatment landscape in the UK for stage III NSCLC.
    Br J Cancer. 2020;123.
    PubMed         Abstract available
    
    
14. PAZ-ARES L
    Summary of 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.
    Br J Cancer. 2020;123.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

15. KAN M, Imaoka H, Watanabe K, Sasaki M, et al
    Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
    Cancer Chemother Pharmacol. 2020;86:203-210.
    PubMed         Abstract available
    
    
16. UCHINO T, Fujino H, Kamiya D, Suzuki T, et al
    Association of dry skin with intercellular lipid composition of stratum corneum after erlotinib administration.
    Cancer Chemother Pharmacol. 2020;86:233-243.
    PubMed         Abstract available
    
    
17. LI C, Hart L, Owonikoko TK, Aljumaily R, et al
    Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
    Cancer Chemother Pharmacol. 2021 Feb 17. pii: 10.1007/s00280-021-04239.
    PubMed         Abstract available
    
    
18. KITO Y, Satake H, Taniguchi H, Yamada T, et al
    Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer.
    Cancer Chemother Pharmacol. 2020;86:277-284.
    PubMed         Abstract available
    
    

    
    Cancer Lett

19. TEOH ST, Ogrodzinski MP, Lunt SY
    UDP-glucose 6-dehydrogenase knockout impairs migration and decreases in vivo metastatic ability of breast cancer cells.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30388.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

20. DATAR IJ, Hauc S, Desai SS, Gianino N, et al
    Spatial analysis and clinical significance of HLA class-I and class-II subunit expression in non-small cell lung cancer.
    Clin Cancer Res. 2021 Feb 18. pii: 1078-0432.CCR-20-3655.
    PubMed         Abstract available
    
    
21. SKWARSKI M, McGowan DR, Belcher E, Di Chiara F, et al
    Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Feb 17. pii: 1078-0432.CCR-20-4128.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

22. OWONIKOKO TK, Redman MW, Byers LA, Hirsch FR, et al
    Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
    Clin Lung Cancer. 2021 Jan 10. pii: S1525-7304(21)00004.
    PubMed         Abstract available
    
    
23. MERRITT RE, Abdel-Rasoul M, D'Souza DM, Kneuertz PJ, et al
    Racial Disparities in Overall Survival and Surgical Treatment for Early Stage Lung Cancer by Facility Type.
    Clin Lung Cancer. 2021 Jan 22. pii: S1525-7304(21)00010.
    PubMed         Abstract available
    
    
24. CHAN SWS, Smith E, Aggarwal R, Balaratnam K, et al
    Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
    Clin Lung Cancer. 2021 Jan 10. pii: S1525-7304(21)00005.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

25. MAZZARELLA L, Giugliano S, D'Amico P, Belli C, et al
    Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity.
    Eur J Cancer. 2020;141:218-224.
    PubMed         Abstract available
    
    
26. THOMPSON LL, Nadelmann ER, Blum AE, Yoon J, et al
    Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer.
    Eur J Cancer. 2021;147:13-16.
    PubMed        
    
    

    
    Hum Pathol

27. HAYASHI T, Kohsaka S, Takamochi K, Hara K, et al
    Clinicopathological characteristics of lung adenocarcinoma with compound EGFR mutations.
    Hum Pathol. 2020;103:42-51.
    PubMed         Abstract available
    
    
28. HERMELIJN SM, Wolf JL, Dorine den Toom T, Wijnen RMH, et al
    Early KRAS oncogenic driver mutations in nonmucinous tissue of congenital pulmonary airway malformations as an indicator of potential malignant behavior.
    Hum Pathol. 2020;103:95-106.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

29. KIM MM, Parmar HA, Schipper M, Devasia T, et al
    BRAINSTORM: A Multi-Institutional Phase I/II Study of RRx-001 in Combination with Whole Brain Radiation Therapy for Patients with Brain Metastases.
    Int J Radiat Oncol Biol Phys. 2020 Mar 10. pii: S0360-3016(20)30890.
    PubMed         Abstract available
    
    
30. NENOFF L, Matter M, Jarhall AG, Winterhalter C, et al
    Daily Adaptive Proton Therapy: Is it Appropriate to Use Analytical Dose Calculations for Plan Adaption?
    Int J Radiat Oncol Biol Phys. 2020;107:747-755.
    PubMed         Abstract available
    
    

    
    J Clin Invest

31. YANG Y, Neo SY, Chen Z, Cui W, et al
    Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells.
    J Clin Invest. 2020;130:5508-5522.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

32. HANNA NH, Robinson AG, Temin S, Baker S Jr, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
    J Clin Oncol. 2021 Feb 16:JCO2003570. doi: 10.1200/JCO.20.03570.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

33. MONTENEGRO GB, Farid S, Liu SV
    Immunotherapy in lung cancer.
    J Surg Oncol. 2021;123:718-729.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

34. YE T, Chen H
    Commentary: The ground-glass opacity: "The savior" for lung cancer?
    J Thorac Cardiovasc Surg. 2021 Jan 8. pii: S0022-5223(21)00014.
    PubMed        
    
    
35. BAZHENOVA L, Urbanic J, Onaitis M
    Commentary: Epidermal growth factor receptor mutations in resectable lung cancer: What is the prognostic importance?
    J Thorac Cardiovasc Surg. 2020 Jul 13. pii: S0022-5223(20)32054.
    PubMed        
    
    

    
    J Thorac Oncol

36. RAY MA, Fehnel C, Akinbobola O, Faris NR, et al
    Comparative Effectiveness of a Lymph Node Collection kit Versus 'Heightened Awareness' on Lung Cancer Surgery Quality and Outcomes.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01665.
    PubMed         Abstract available
    
    
37. AREDO JV, Mambetsariev I, Hellyer JA, Amini A, et al
    Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01702.
    PubMed         Abstract available
    
    
38. HENDERSON LM, Durham DD, Tammemagi MC, Benefield T, et al
    Lung Cancer Screening with Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial.
    J Thorac Oncol. 2021 Feb 10. pii: S1556-0864(21)01703.
    PubMed         Abstract available
    
    
39. YE L, Creaney J, Redwood A, Robinson B, et al
    The current lung cancer neoantigen landscape and implications for therapy.
    J Thorac Oncol. 2021 Feb 10. pii: S1556-0864(21)01698.
    PubMed         Abstract available
    
    
40. RADONIC T, Geurts-Giele WRR, Samsom KG, Roemen GMJM, et al
    RET FISH analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01666.
    PubMed         Abstract available
    
    
41. ZHANG Y, Luo G, Etxeberria J, Hao Y, et al
    Global patterns and trends in lung cancer incidence: a population-based study.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01700.
    PubMed         Abstract available
    
    
42. YUN JK, Lee GD, Choi S, Kim YH, et al
    A Validation Study on the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients with pN2 Non-small Cell Lung Cancer.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01668.
    PubMed         Abstract available
    
    
43. OSAROGIAGBON RU, Smeltzer MP, Faris NR, Ray MA, et al
    Outcomes Following Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01658.
    PubMed         Abstract available
    
    
44. BLACKHALL F, Jao K, Greillier L, Cho BC, et al
    Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01709.
    PubMed         Abstract available
    
    
45. YANG Y, Huang J, Wang T, Zhou J, et al
    Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01662.
    PubMed         Abstract available
    
    

    
    Lancet

46. SEZER A, Kilickap S, Gumus M, Bondarenko I, et al
    Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
    Lancet. 2021;397:592-604.
    PubMed         Abstract available
    
    
47. ROSELL R, Gonzalez-Cao M
    Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer.
    Lancet. 2021;397:557-559.
    PubMed        
    
    

    
    Lancet Oncol

48. CHO BCJ, Donahoe L, Bradbury PA, Leighl N, et al
    Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.
    Lancet Oncol. 2021;22:190-197.
    PubMed         Abstract available
    
    

    
    Lung Cancer

49. HENG WS, Pore M, Meijer C, Hiltermann TJN, et al
    A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker.
    Lung Cancer. 2021;154:13-22.
    PubMed         Abstract available
    
    

    
    N Engl J Med

50. SCHWARTZSTEIN RM, Medoff BD, Sharma A, Colson YL, et al
    Case 4-2021: A 70-Year-Old Woman with Dyspnea on Exertion and Abnormal Findings on Chest Imaging.
    N Engl J Med. 2021;384:563-574.
    PubMed        
    
    
51. LIANG W, Zhong R, He J
    Osimertinib in EGFR-Mutated Lung Cancer.
    N Engl J Med. 2021;384:675.
    PubMed        
    
    
52. HERBST RS, Wu YL, Tsuboi M
    Osimertinib in EGFR-Mutated Lung Cancer. Reply.
    N Engl J Med. 2021;384:675-676.
    PubMed        
    
    
53. KARAPOLAT S, Sisman M
    Heart-Shaped Lesion.
    N Engl J Med. 2021;384:562.
    PubMed        
    
    

    
    Nat Med

54. CASCONE T, William WN Jr, Weissferdt A, Leung CH, et al
    Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
    Nat Med. 2021 Feb 18. pii: 10.1038/s41591-020-01224.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

55. LEE J, Lee D, Lawler S, Kim Y, et al
    Role of neutrophil extracellular traps in regulation of lung cancer invasion and metastasis: Structural insights from a computational model.
    PLoS Comput Biol. 2021;17:e1008257.
    PubMed         Abstract available
    
    

    
    PLoS One

56. LEI Z, Yang W, Zuo Y
    Beta-blocker and survival in patients with lung cancer: A meta-analysis.
    PLoS One. 2021;16:e0245773.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: